Suppr超能文献

位点特异性抗体药物偶联物中缬氨酸-瓜氨酸-PABC连接子不稳定性的分子基础及其通过连接子设计的缓解

Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.

作者信息

Dorywalska Magdalena, Dushin Russell, Moine Ludivine, Farias Santiago E, Zhou Dahui, Navaratnam Thayalan, Lui Victor, Hasa-Moreno Adela, Casas Meritxell Galindo, Tran Thomas-Toan, Delaria Kathy, Liu Shu-Hui, Foletti Davide, O'Donnell Christopher J, Pons Jaume, Shelton David L, Rajpal Arvind, Strop Pavel

机构信息

Rinat Laboratories, Pfizer Inc., South San Francisco, California.

Worldwide Medicinal Chemistry, Pfizer Inc., Groton, Connecticut.

出版信息

Mol Cancer Ther. 2016 May;15(5):958-70. doi: 10.1158/1535-7163.MCT-15-1004. Epub 2016 Mar 4.

Abstract

The degree of stability of antibody-drug linkers in systemic circulation, and the rate of their intracellular processing within target cancer cells are among the key factors determining the efficacy of antibody-drug conjugates (ADC) in vivo Previous studies demonstrated the susceptibility of cleavable linkers, as well as auristatin-based payloads, to enzymatic cleavage in rodent plasma. Here, we identify Carboxylesterase 1C as the enzyme responsible for the extracellular hydrolysis of valine-citrulline-p-aminocarbamate (VC-PABC)-based linkers in mouse plasma. We further show that the activity of Carboxylesterase 1C towards VC-PABC-based linkers, and consequently the stability of ADCs in mouse plasma, can be effectively modulated by small chemical modifications to the linker. While the introduced modifications can protect the VC-PABC-based linkers from extracellular cleavage, they do not significantly alter the intracellular linker processing by the lysosomal protease Cathepsin B. The distinct substrate preference of the serum Carboxylesterase 1C offers the opportunity to modulate the extracellular stability of cleavable ADCs without diminishing the intracellular payload release required for ADC efficacy. Mol Cancer Ther; 15(5); 958-70. ©2016 AACR.

摘要

抗体-药物连接子在体循环中的稳定程度以及它们在靶癌细胞内的胞内加工速率是决定抗体-药物偶联物(ADC)体内疗效的关键因素。以往研究表明,可裂解连接子以及基于澳瑞他汀的有效载荷在啮齿动物血浆中易受酶解作用影响。在此,我们确定羧酸酯酶1C是负责小鼠血浆中基于缬氨酸-瓜氨酸-对氨基甲酸酯(VC-PABC)连接子胞外水解的酶。我们进一步表明,通过对连接子进行小的化学修饰,可以有效调节羧酸酯酶1C对基于VC-PABC连接子的活性,进而调节ADC在小鼠血浆中的稳定性。虽然引入的修饰可以保护基于VC-PABC的连接子免受胞外裂解,但它们不会显著改变溶酶体蛋白酶组织蛋白酶B对连接子的胞内加工。血清羧酸酯酶1C独特的底物偏好提供了一个机会,可在不降低ADC疗效所需的胞内有效载荷释放的情况下,调节可裂解ADC的胞外稳定性。《分子癌症治疗》;15(5);958 - 70。©2016美国癌症研究协会。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验